Venn Life Sciences €3.2m contract win with global pharma company

What is respiratory syncytial virus (RSV) in children? RSV is a respiratory virus that causes illness and trouble breathing. It is more common in winter and early spring months and can be which can be life-threatening in babies and

In 1918, about 50 million people, or one-fifth of the world’s population, became infected with the virus known as the “Spanish” flu, according to the Centers for Disease Control and Prevention (CDC). “The 1918 Pandemic was the reason the military was

Asthma sufferers will often avoid exercise, fearing that it will worsen their condition or induce an asthma attack. Whilst it can be the case that exercise triggers symptoms, this should not be a reason for it to be

Influenza isn’t just limited to certain areas of the world. The flu virus leads to nearly 40 million flu-related illnesses each year even though it is one of the most preventable diseases. It can be found in Asia and

The European Medicines Agency (EMA) published an updated Guideline on clinical evaluation of vaccines (EMEA/ CHMP/VWP/164653/05 Rev. 1). This guideline was updated following EMA` s experience in the past decade with new vaccines applications, including the approval of

hVIVO has signed a new testing contract with an Asia-Pacific based drug maker, which it says is an indication of its growing regional client base. The UK contract research organisation (CRO) shared minimal details of the £6.8 million

There are several distinctive features that must be considered in the ATMP development: ATMPs are mainly for the unmet medical needs = severe, rare, or chronic diseases with no adequate conventional treatments. Risk-based approach = Dominant strategy of

Over 25 years Venn Life Sciences have built up substantial therapeutic and study experience, contributing to the efficient management of sites, budgets and communication channels. Venn is renowned for its hands-on approach and consistent delivery of high quality

Reproduced from an online seminar presentation, made in collaboration with TOPRA and hVIVO, given on 21 June 2022 by Bruno Speder from hVIVO. Despite advancement in global pharmaceutical research, nearly one billion individuals are affected by tropical diseases yearly,

CRO hVIVO inked a 6.8 million pounds sterling ($8.2 million) deal with an unnamed pharmaceutical company to run a human challenge test for a respiratory syncytial virus (RSV) antiviral drug candidate. The study will be conducted at hVIVO’s

hVIVO, an Irish-founded research organisation, has signed a major contract worth £6.8 million (€7.6 million) to test vaccines. The company, formerly known as Open Orpahn, said the deal was with a “leading pharmaceutical company based in Asia Pacific”,

Hvivo landed its second contract this year with a pharmaceutical company based in Asia Pacific. The AIM-listed clinical trial specialist has identified the region as a ‘key growth area’. As part of a £6.8million deal, Hvivo will recruit

Investors in Irish financier Cathal Friel’s drug research venture hVIVO are set for a payback after double-digit revenue growth last year. Mr Friel is the founder of Raglan Capital, which specialises in creating in-house pharmaceutical companies that it